StockNews.com initiated coverage of Alimera Sciences, assigning the biopharmaceutical company a “hold” rating, while HC Wainwright reiterated a “buy” rating with a $9.00 price target on Alimera Sciences shares. Alimera Sciences has a 1-year low of $1.30 and a 1-year high of $7.92. Insiders own 12.90% of the company’s stock, while institutional investors and hedge funds have recently added or reduced their stakes in the company. Alimera Sciences develops ophthalmic pharmaceuticals to treat various eye conditions. To receive daily updates on the latest news and ratings for Alimera Sciences and related companies, you can subscribe to MarketBeat.com’s FREE daily email newsletter.
StockNews.com has initiated coverage of Alimera Sciences (NASDAQ:ALIM) by assigning a “hold” rating to the company’s biopharmaceutical shares in a research report published on Wednesday. HC Wainwright, on the other hand, has reiterated a “buy” rating and set a $9.00 price target on Alimera Sciences shares in a research report dated February 23, 2023. Alimera Sciences shares opened at $1.95 on Wednesday, having a 1-year low of $1.30 and a 1-year high of $7.92. The company currently has a market capitalization of $13.65 million, a price-to-earnings ratio of -0.74, and a beta of 1.42. Alimera Sciences’ 50-day moving average price stands at $2.24, while its two-hundred day moving average price is $3.56.
In March 2023, Alto Investors Lp Palo, a major shareholder, sold 200,919 Alimera Sciences shares at an average price of $1.56, for a total transaction value of $313,433.64. Insiders, overall, own 12.90% of the company’s stock. On the other hand, institutional investors and hedge funds have recently decreased or increased their stake in the company, including Millennium Management LLC, which acquired a new stake in Alimera Sciences valued at $32,000 during the 4th quarter, and Susquehanna International Group LLP, which acquired a new stake in Alimera Sciences valued at $92,000 during the same quarter. Renaissance Technologies LLC, which raised its stake in Alimera Sciences by 2.3% during the 2nd quarter, now owns 127,693 shares of the company’s stock, worth $698,000, after purchasing an additional 2,900 shares during the period. Caligan Partners LP, meanwhile, acquired a new stake in Alimera Sciences valued at $1,297,000 during the 4th quarter. Overall, 24.58% of Alimera Sciences’ stock is owned by institutional investors and hedge funds.
Alimera Sciences engages in the research and development of biopharmaceutical products. The company focuses on ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion.
Get a brief daily summary of the latest news and analysts’ ratings for Alimera Sciences and related companies by subscribing to MarketBeat.com’s FREE daily email newsletter. Simply enter your email address to receive updates.
Don’t miss interesting posts on Famousbio
